- MVSR and PanGenex pool resources sale of LIPIDEME(TM)

Stock Ideas

Wall Street Stock Ideas

MVSR and PanGenex pool resources sale of LIPIDEME(TM)

Stock Ideas

Market Watch

Start your research on DKSC by looking at this 2 month chart: You can clearly see that the volume and price is slowly moving up. Keep in mind that DKSC just announced last week the signing of a sales agreement for $48 million!!!
More...

Login Form

MVSR and PanGenex pool resources sale of LIPIDEME(TM)

Monday, 22 September 2008

Make sure MVSR is on your watch list, if the market rallies hard MVSR could follow! The global pharmaceuticals market was estimated at estimated at $554 billion in 2004! With the industry spending over $14 billion annually on detailing, there is increased pressure on pharmaceutical companies to find new, profitable techniques for reaching physicians and building revenues
MVSR is working in a very profitable industry.
This is where MVSR comes in.

MVSR does not manufacture any drugs, but they focus on the sales and marketing of drugs to physicians.

This is actually better than be a pharmaceutical company. If a bio company has only 1 drug product and that drug fails in clinical trials the whole company could fail!

Pharmaceutical companies can use MVSR from pre-product development through product launch and commercialization.

MVSR specializes in medical marketing consulting, graphic design, web site marketing strategy, event management, public relations and market research.

MVSR offers worldwide experience in delivering effective and successful integrated marketing and creative communications campaigns for the mutual benefit of both pharmaceutical vendors as well as the practitioners.

MVSR knows that physicians play a very important role in pharmaceutical sales. They decide what to prescribe to their patients.

MVSR cost-effectively reaches the full spectrum of physicians who will find it easy and convenient to learn about a company's pharmaceutical products.

Through e-detailing, MVSR provides physicians presentations of different pharmaceutical drugs.

Physicians just have to log into MVSR's website to view the presentations.

Profit from China's economic growth

By Graham Summers China's in quite a quandary. It wants the rapid economic growth of a market-based economy. But at the same time, it wants to retain its iron clutch over its 1+ billion...
+ Full Story

How to Measure "Cheap"

By George Kleinman Last week, the Dow Jones Industrial Average suffered its worst weekly loss in five years with a 4 percent drop. The Dow is now down 8 percent from its highs, but it's still up...
+ Full Story

To view a power point representation and see how MVSR works, click here:

MVSR has signed several agreements that could lead to huge profits in the future, including a a revenue sharing agreement for the marketing and sale of LIPIDEME(TM) with PanGenex Corporation.

PanGenex is a publicly traded corporation that pursues business opportunities in the $70 billion nutraceutical and dietary supplement industry.

The terms of the Agreement call for MVSR and PanGenex to pool collective resources for the marketing and sale of LIPIDEME(TM), a synergistic blend of ingredients designed to lower cholesterol four ways.

The American Heart Association estimates that nearly 140 million Americans have either borderline-high or high!

In 2003, approximately 22 million people took a medication to try to lower their cholesterol.

MVSR CEO Dino Luzzi stated, "We are very pleased that PanGenex has selected Medivisor to market and sell LIPIDIME. Under this agreement our main objective will be to contribute to the sales growth of LIPIDIME through both US and International distribution channels. This will also drive further revenue and profits for Medivisor."

MVSR intends to increase awareness for LIPIDEME(TM) in Italy. Since signing the initial revenue sharing agreement with PanGenex Corporation, Medivisor has gathered initial interest for the product and expects to begin shipping samples later in the month.

MVSR also wants to tap into the billion dollar energy drink sector.

MVSR intends to begin marketing its own targeted energy drink initially throughout the European continent.

The energy drink market is one of the trendiest and fastest growing segments within the overall beverage market.

According to Market Research Group, the energy drink category has grown by 440% since 2002 to a whopping $6.6 billion in 2007 and is expected to reach $9 billion in 2011!

MVSR's yet to be named product will be launched in Italy within the shot category of the energy drink market.

The shot category is experiencing tremendous growth due to the fact that at only two ounces, you get more energy and have less to drink than with the larger canned competitors.

MVSR CEO Dino Luzzi said, "We look to set this product apart from the competition by including a formula blend with Acai. Recently, the remarkable health benefits of Acai have been validated by modern science. Because of its superior nutrient content and unparalleled antioxidant levels, Acai is now widely regarded as one of the world's top superfoods."

More information on MVSR is available at their website:
From: Hototc.com This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

We endeavor to decipher analysis of this Teaser/News Letter to distinguish the thoughts of Authors/Editors.
Please post your Review/Comments, your rating helps other users gauge the value of an article ...